[
  {
    "ts": null,
    "headline": "3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now",
    "summary": "These dividend stocks provide consistent income and long-term stability.",
    "url": "https://finnhub.io/api/news?id=aa17fb9f1358d31de0542acd0a33c3e430c423831e7e49b36f453fc69955eb33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751499002,
      "headline": "3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now",
      "id": 135735564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These dividend stocks provide consistent income and long-term stability.",
      "url": "https://finnhub.io/api/news?id=aa17fb9f1358d31de0542acd0a33c3e430c423831e7e49b36f453fc69955eb33"
    }
  },
  {
    "ts": null,
    "headline": "Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data",
    "summary": "Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data",
    "url": "https://finnhub.io/api/news?id=e9bfa3927d065e1d32eca7f8edc283b21f44a5578e6432e9946e29cc5f1ddcf6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751491380,
      "headline": "Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data",
      "id": 135718429,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e9bfa3927d065e1d32eca7f8edc283b21f44a5578e6432e9946e29cc5f1ddcf6"
    }
  },
  {
    "ts": null,
    "headline": "THQ: Valuation Remains Unappealing Even If Portfolio Is Beaten-Down",
    "summary": "THQ struggles with healthcare sector underperformance and trades at a premium. Read the full report on why THQ's high yield may face challenges.",
    "url": "https://finnhub.io/api/news?id=04c7bf0158dca8563c770c83f1f06a210e91409842a5d6e2d8ce42452ec973e9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751472824,
      "headline": "THQ: Valuation Remains Unappealing Even If Portfolio Is Beaten-Down",
      "id": 135715852,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203781634/image_2203781634.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "THQ struggles with healthcare sector underperformance and trades at a premium. Read the full report on why THQ's high yield may face challenges.",
      "url": "https://finnhub.io/api/news?id=04c7bf0158dca8563c770c83f1f06a210e91409842a5d6e2d8ce42452ec973e9"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Alphabet, AbbVie and The Walt Disney",
    "summary": "GOOGL, ABBV, and DIS face rising costs and competition, but strong cloud, immunology, and parks growth continue to fuel optimism.",
    "url": "https://finnhub.io/api/news?id=48d5b0f310d2882409f1e63bc516d0df8511b0be47118ce0c49722c9f99516ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751467560,
      "headline": "The Zacks Analyst Blog Highlights Alphabet, AbbVie and The Walt Disney",
      "id": 135714117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "GOOGL, ABBV, and DIS face rising costs and competition, but strong cloud, immunology, and parks growth continue to fuel optimism.",
      "url": "https://finnhub.io/api/news?id=48d5b0f310d2882409f1e63bc516d0df8511b0be47118ce0c49722c9f99516ba"
    }
  },
  {
    "ts": null,
    "headline": "Why AbbVie (ABBV) is a Top Value Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=0f1b75e883ee5de69e5016988daa46f2111f1d3185b581929dcfe5a42c26352d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751463602,
      "headline": "Why AbbVie (ABBV) is a Top Value Stock for the Long-Term",
      "id": 135714118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=0f1b75e883ee5de69e5016988daa46f2111f1d3185b581929dcfe5a42c26352d"
    }
  },
  {
    "ts": null,
    "headline": "Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?",
    "summary": "JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.",
    "url": "https://finnhub.io/api/news?id=24cb13285fa35443fd672da62e4a29e62c4ac68bae73b5f24b0d49ebc1d4c128",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751461620,
      "headline": "Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?",
      "id": 135713902,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.",
      "url": "https://finnhub.io/api/news?id=24cb13285fa35443fd672da62e4a29e62c4ac68bae73b5f24b0d49ebc1d4c128"
    }
  },
  {
    "ts": null,
    "headline": "Will AbbVie's Acquisition Spree Aid Pipeline Growth?",
    "summary": "ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.",
    "url": "https://finnhub.io/api/news?id=323e3788c281ffd783e10e7ffb52dc8e71c27b8c917a971f6f8edbeb356d1644",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751460360,
      "headline": "Will AbbVie's Acquisition Spree Aid Pipeline Growth?",
      "id": 135712714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.",
      "url": "https://finnhub.io/api/news?id=323e3788c281ffd783e10e7ffb52dc8e71c27b8c917a971f6f8edbeb356d1644"
    }
  },
  {
    "ts": null,
    "headline": "Exploring 3 High Growth Tech Stocks In The US Market",
    "summary": "The United States market has shown a positive trajectory, climbing 2.9% in the last week and up 14% over the past year, with earnings anticipated to grow by 15% annually in the coming years. In this context of robust market performance, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation within this dynamic sector.",
    "url": "https://finnhub.io/api/news?id=9b67c0e4eb489db77701f748e3fc6c58a95bbbe70a2bfd33dc22300492cbb146",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751456303,
      "headline": "Exploring 3 High Growth Tech Stocks In The US Market",
      "id": 135710939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The United States market has shown a positive trajectory, climbing 2.9% in the last week and up 14% over the past year, with earnings anticipated to grow by 15% annually in the coming years. In this context of robust market performance, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation within this dynamic sector.",
      "url": "https://finnhub.io/api/news?id=9b67c0e4eb489db77701f748e3fc6c58a95bbbe70a2bfd33dc22300492cbb146"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Tax Triumph: Breaking Free From Capital Loss Limitations",
    "summary": "Highlights The U.S. Tax Court recently issued an opinion in AbbVie Inc. v. Commissioner, Docket No. 2597-23, allowing the approximately $1.6 billion Break Fee paid by AbbVie to be treated as an...",
    "url": "https://finnhub.io/api/news?id=4d5846bd069ce8ea7f04aded25ebc5874545455b0e03aea416358afe54ff3407",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751451011,
      "headline": "AbbVie's Tax Triumph: Breaking Free From Capital Loss Limitations",
      "id": 135712194,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Highlights The U.S. Tax Court recently issued an opinion in AbbVie Inc. v. Commissioner, Docket No. 2597-23, allowing the approximately $1.6 billion Break Fee paid by AbbVie to be treated as an...",
      "url": "https://finnhub.io/api/news?id=4d5846bd069ce8ea7f04aded25ebc5874545455b0e03aea416358afe54ff3407"
    }
  }
]